Nuvalent, Inc.
NUVL
주식 순위
#2106
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
주가
$123.96
마지막 동기화: 2026-07-21
시가총액
$9.75B
변동 (1일)
0.00%
변동 (1년)
26.53%
국가
US
거래 Nuvalent, Inc. (NUVL)
카테고리
Healthcare
Nuvalent, Inc. (NUVL)의 배당 수익률 기록
Nuvalent, Inc. (주식 심볼: NUVL)의 배당 수익률 (TTM)은 2023-12-31 기준으로 0.00%입니다.
지난 5년 평균 배당 수익률: 0.00%
지난 5년 평균 배당 수익률: 0.00%
Nuvalent, Inc. (NUVL)의 배당 수익률 기록: 2019 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
| 연도 | 배당 수익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
| 회사 | 배당 수익률 | 국가 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
